Pharmaceutical

Biogen bids farewell to Aduhelm after tumultuous journey in Alzheimer’s

The shelving of Biogen’s troubled Alzheimer’s drug caps a turbulent journey, with Leqembi now receiving the company’s full attention.

Jan 31, 2024 - 18:00
Biogen bids farewell to Aduhelm after tumultuous journey in Alzheimer’s
The shelving of Biogen’s troubled Alzheimer’s drug caps a turbulent journey, with Leqembi now receiving the company’s full attention.
Read the original article

Tags:

Previous Article

Defender’s plans for motion sickness nasal gel stop with FDA rejection

Next Article

Phase III study halted: Ferrer’s oral edaravone disappoints in ALS

What's Your Reaction?

like

dislike

love

funny

angry

sad

wow

Related Posts

STAT+: ARPA-H head Renee Wegrzyn on the agency’s new Cambridge hub and plans for cancer research

STAT+: ARPA-H head Renee Wegrzyn on the agency’s new Ca...

Oct 28, 2023

STAT+: Judge skeptical of arguments against Medicare drug price negotiation

STAT+: Judge skeptical of arguments against Medicare dr...

Feb 1, 2024

STAT+: Inside Ascension’s legal fight with a Texas agency over caring for the poor

STAT+: Inside Ascension’s legal fight with a Texas agen...

Jan 2, 2024